These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 34915496)

  • 21. Corticosteroid Responsiveness Following Mepolizumab in Severe Eosinophilic Asthma-A Randomized, Placebo-Controlled Crossover Trial (MAPLE).
    Yang F; Busby J; Heaney LG; Pavord ID; Brightling CE; Borg K; McDowell JP; Diver SE; Shrimanker R; Bradding P; Shepherd M; Chaudhuri R;
    J Allergy Clin Immunol Pract; 2022 Nov; 10(11):2925-2934.e12. PubMed ID: 35863669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mepolizumab in children and adolescents with severe eosinophilic asthma not eligible for omalizumab: a single Center experience.
    Lim YT; Williams TC; Langley RJ; Weir E
    J Asthma; 2024 Aug; 61(8):793-800. PubMed ID: 38240489
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-World Effectiveness of Mepolizumab in Severe Asthma: Results from the Multi-country, Self-controlled Nucala Effectiveness Study (NEST).
    Al-Lehebi RO; Al Ahmad M; Maturu VN; Mesa AG; Mahboub B; Garcia E; Fernandez P; Soares C; Abreu G; Dos Santos D; Queiroz J; Raimondi A; Laucho-Contreras M; Noibi S; Levy G; Bavbek S
    Adv Ther; 2024 Nov; 41(11):4008-4031. PubMed ID: 39215767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term retention rate of mepolizumab treatment in severe asthma: a 36-months real-life experience.
    Matucci A; Vivarelli E; Bormioli S; Francesca N; Chiccoli F; Valentina M; Francesca G; Oliviero R; Parronchi P; Vultaggio A
    J Asthma; 2023 Jan; 60(1):158-166. PubMed ID: 35112934
    [No Abstract]   [Full Text] [Related]  

  • 25. A real-life cohort of mepolizumab treatment in severe eosinophilic asthma.
    Laorden D; Hernández I; Domínguez-Ortega J; Romero D; Álvarez-Sala R; Quirce S
    Eur Ann Allergy Clin Immunol; 2024 Jul; 56(4):169-175. PubMed ID: 36927725
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study.
    Numata T; Miyagawa H; Nishioka S; Okuda K; Utsumi H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
    BMC Pulm Med; 2020 Aug; 20(1):207. PubMed ID: 32746787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study.
    Pelaia C; Busceti MT; Solinas S; Terracciano R; Pelaia G
    Pulm Pharmacol Ther; 2018 Dec; 53():1-5. PubMed ID: 30217438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study.
    Khurana S; Brusselle GG; Bel EH; FitzGerald JM; Masoli M; Korn S; Kato M; Albers FC; Bradford ES; Gilson MJ; Price RG; Humbert M
    Clin Ther; 2019 Oct; 41(10):2041-2056.e5. PubMed ID: 31447130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sinonasal and respiratory outcomes of eosinophilic granulomatosis with polyangiitis patients receiving 100 mg mepolizumab in real-life clinical practice: 1-year follow up study.
    Can Bostan O; Duran E; Tuncay G; Cihanbeylerden M; Karadag O; Damadoglu E; Karakaya G; Kalyoncu AF
    J Asthma; 2023 May; 60(5):931-937. PubMed ID: 35912568
    [No Abstract]   [Full Text] [Related]  

  • 30. Real-life effectiveness of mepolizumab in severe asthma: a systematic literature review.
    Israel E; Canonica GW; Brusselle G; Yang S; Howarth PH; Martin AL; Koufopoulou M; Smith SG; Alfonso-Cristancho R
    J Asthma; 2022 Nov; 59(11):2201-2217. PubMed ID: 34951336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting.
    Cameli P; Bergantini L; d'Alessandro M; Perruzza M; Cekorja B; Perillo F; Massa E; Ruzza A; Fossi A; Beltrami V; Sestini P; Bargagli E
    Int Arch Allergy Immunol; 2020; 181(8):606-612. PubMed ID: 32516771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities.
    Crimi C; Campisi R; Cacopardo G; Intravaia R; Nolasco S; Porto M; Pelaia C; Crimi N
    World Allergy Organ J; 2020 Sep; 13(9):100462. PubMed ID: 32994855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of mepolizumab therapy on symptoms, asthma exacerbations, steroid dependence, and small airways in patients with severe eosinophilic asthma.
    Yılmaz İ; Nazik Bahçecioğlu S; Türk M; Tutar N; Paçacı Çetin G; Arslan B
    Turk J Med Sci; 2021 Aug; 51(4):1953-1959. PubMed ID: 33932968
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study.
    Pavord I; Gardiner F; Heaney LG; Domingo C; Price RG; Pullan A; Oppenheimer J; Brusselle G; Nagase H; Chupp G; Pizzichini E; Bañas-Conejero D; Howarth P
    Front Immunol; 2023; 14():1150162. PubMed ID: 37122713
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
    Liu MC; Chipps B; Munoz X; Devouassoux G; Bergna M; Smith SG; Price RG; Galkin DV; Azmi J; Mouneimne D; Albers FC; Chapman KR
    Respir Res; 2021 May; 22(1):144. PubMed ID: 33971856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proportion of Severe Asthma Patients Eligible for Mepolizumab Therapy by Age and Age of Onset of Asthma.
    Comberiati P; McCormack K; Malka-Rais J; Spahn JD
    J Allergy Clin Immunol Pract; 2019; 7(8):2689-2696.e2. PubMed ID: 31201938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment.
    Magnan A; Bourdin A; Prazma CM; Albers FC; Price RG; Yancey SW; Ortega H
    Allergy; 2016 Sep; 71(9):1335-44. PubMed ID: 27087007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world characteristics of "super-responders" to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis.
    Portacci A; Campisi R; Buonamico E; Nolasco S; Pelaia C; Crimi N; Benfante A; Triggiani M; Spadaro G; Caiaffa MF; Scioscia G; Detoraki A; Valenti G; Papia F; Tomasello A; Scichilone N; Pelaia G; Crimi C; Carpagnano GE
    ERJ Open Res; 2023 Sep; 9(5):. PubMed ID: 37908397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype.
    Pelaia C; Crimi C; Pelaia G; Nolasco S; Campisi R; Heffler E; Valenti G; Crimi N
    Clin Exp Allergy; 2020 Jul; 50(7):780-788. PubMed ID: 32347992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral corticosteroid-sparing effects of mepolizumab in severe eosinophilic asthma: evidence from randomized controlled trials and real-world studies.
    Casale TB; Burnette A; Bourdin A; Howarth P; Hahn B; Stach-Klysh A; Khurana S
    Ther Adv Respir Dis; 2022; 16():17534666221107313. PubMed ID: 35972211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.